Skip to main content
. 2020 Feb 3;15(2):e0228685. doi: 10.1371/journal.pone.0228685

Fig 5. Effects of the propranolol treatment on fat mass and glucose metabolism in mice fed HSHFD for 8 weeks.

Fig 5

(A) Data on body weight and calorie intake from mice with or without propranolol (Propra). Body weight was measured 8 weeks after ND or HSHFD feeding. Food intake was collected for 3 days on days 54 to 56 after ND or HSHFD feeding was started and shown as a representative of the average daily calorie intake. (B) Fat mass in the whole body of mice with or without propranolol was assessed by QCT 8 weeks after ND or HSHFD feeding was started. The tissue weight of epididymal WAT was measured 8 weeks after ND or HSHFD feeding. (C) The cross-sectional area (CSA) of adipocytes in the epididymal WAT of mice with or without propranolol 8 weeks after ND or HSHFD feeding was started. (D) Total RNA was extracted from the epididymal WAT of mice with or without propranolol 8 weeks after ND or HSHFD feeding was started. A real-time PCR analysis was then performed. Data are expressed relative to the levels of 18S rRNA. (E) Fasting blood glucose and serum insulin levels were measured 8 weeks after ND or HSHFD feeding was started. (F, G) Responses of blood glucose to a single intraperitoneal injection of glucose (F) and insulin (G) in mice with or without propranolol 8 weeks after ND or HSHFD feeding was started. The area under the curve (AUC) for 120 min was calculated. Cont; control. *P < 0.05 and **P < 0.01; ¶P < 0.05 and ¶¶P < 0.01, vs ND/Control; #P < 0.05 and ##P < 0.01, vs HSHFD/Propranolol (Tukey-Kramer test). Data represent the mean ± SEM of 8 mice in each group.